Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

34.80 +1.84 (+5.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,592,375
Open 32.10
Bid (Size) 34.85 (100)
Ask (Size) 34.90 (100)
Prev. Close 32.96
Today's Range 32.00 - 35.19
52wk Range 18.92 - 43.15
Shares Outstanding 99,581,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Eli Lilly Secures Landmark FDA Approval for Oral Weight-Loss Pill, Sending Shares Soaring
Shares of Eli Lilly and Company (NYSE: LLY) surged 3.8% on Wednesday following the milestone FDA approval of Foundayo (orforglipron), the first once-daily oral weight-loss pill that does not require... 
Via MarketMinute
Topics Economy
News headline image
2 Healthcare Stocks Wall Street Analysts Say Could Rally 60% or More ↗
There are some tempting bargains if you know where to look. 
Via The Motley Fool

Performance

YTD
-1.8%
-1.8%
1 Month
+4.4%
+4.4%
3 Month
-1.1%
-1.1%
6 Month
+27.1%
+27.1%
1 Year
+45.5%
+45.5%

More News

Read More
News headline image
1 Reason This Biotech Stock Could Triple Before Year-End ↗
Via The Motley Fool
News headline image
Why Viking Therapeutics Stock Could Take Off Later This Year ↗
Via The Motley Fool
News headline image
Goldman Sachs Bullish Forecast: 15% Increase in 2026 U.S. M&A Activity
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Small-Cap Resilience: Russell 2000 Surges 3% as Geopolitical Tensions Ease and ‘Risk-On’ Appetite Returns
Via MarketMinute
Topics ETFs Economy Stocks
News headline image
Got $1,500? Is It Better to Buy Bitcoin, or Viking Therapeutics? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics ↗
Via The Motley Fool
News headline image
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Companies at the Forefront of the GLP-1 Pill Wars ↗
Via MarketBeat
News headline image
Here's Why Viking Therapeutics Stock Recovered and Can Soar 2026 ↗
Via The Motley Fool
News headline image
VKTX Stock Extends Red-Hot Streak: Insider Scoops Up Shares As Multiple Phase 3 Trials Loom This Year In Obesity Race ↗
Via Stocktwits
News headline image
The Great Rotation: Russell 2000 Surges as Investors Flee Overstretched Tech Giants
Via MarketMinute
Topics Artificial Intelligence Bankruptcy ETFs
News headline image
Viking CEO Sees Its Obesity Drug Beating Novo's Wegovy In Weight Loss ↗
Via Stocktwits
News headline image
The $1.35 Trillion Wall: Why Small-Caps are Faltering as the S&P 500 Defies Gravity
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Forget AI Stocks: This Potentially Disruptive Biotech Could Soar By 181%, According to Wall Street ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026
Via Finterra
Topics Economy Intellectual Property
News headline image
Viking Therapeutics: The High-Stakes Weight Loss Contender ↗
Via MarketBeat
News headline image
Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. ↗
Via The Motley Fool
News headline image
Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making. ↗
Via The Motley Fool
News headline image
Novo Nordisk Shares Tumble 15.1% After CagriSema Fails to Topple Eli Lilly in Head-to-Head Trial
Via MarketMinute
News headline image
Why Viking Therapeutics Stock Is Up More Than 9% Today ↗
Via The Motley Fool
News headline image
Eli Lilly Surges as Novo Nordisk’s "CagriSema" Stumbles in High-Stakes Obesity Head-to-Head
Via MarketMinute
News headline image
Novo Nordisk Shares Plunge 13% as Next-Gen Weight Loss Drug CagriSema Fails to Topple Eli Lilly in Landmark Trial
Via MarketMinute
Topics Earnings
News headline image
3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds ↗
Via The Motley Fool

Frequently Asked Questions

Is Viking Therapeutics, Inc. - Common Stock publicly traded?
Yes, Viking Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Viking Therapeutics, Inc. - Common Stock trade on?
Viking Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Viking Therapeutics, Inc. - Common Stock?
The ticker symbol for Viking Therapeutics, Inc. - Common Stock is VKTX on the Nasdaq Stock Market
What is the current price of Viking Therapeutics, Inc. - Common Stock?
The current price of Viking Therapeutics, Inc. - Common Stock is 34.80
When was Viking Therapeutics, Inc. - Common Stock last traded?
The last trade of Viking Therapeutics, Inc. - Common Stock was at 04/02/26 04:00 PM ET
What is the market capitalization of Viking Therapeutics, Inc. - Common Stock?
The market capitalization of Viking Therapeutics, Inc. - Common Stock is 3.47B
How many shares of Viking Therapeutics, Inc. - Common Stock are outstanding?
Viking Therapeutics, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.